Abstract
Activation of the epidermal growth factor receptor (EGFR) not only initiates multiple signal-transduction pathways, including the MAP kinase (MAPK) pathway, but also triggers trafficking events that relocalize receptors from the cell surface to intracellular endocytic compartments. In this paper, we demonstrate that leucine-rich repeat kinase LRRK1, which contains a MAPKKK-like kinase domain, forms a complex with activated EGFR through an interaction with Grb2. Subsequently, LRRK1 and epidermal growth factor (EGF) are internalized and co-localized in early endosomes. LRRK1 regulates EGFR transport from early to late endosomes and regulates the motility of EGF-containing early endosomes in a manner dependent on its kinase activity. Furthermore, LRRK1 serves as a scaffold facilitating the interaction of EGFR with the endosomal sorting complex required for transport-0 complex, thus enabling efficient sorting of EGFR to the inner vesicles of multivesicular bodies. Our findings provide the first evidence that a MAPKKK-like protein regulates the endosomal trafficking of EGFR.
Similar content being viewed by others
Introduction
Binding of epidermal growth factor (EGF) to its cell surface receptor (EGFR) results in the activation of numerous cell signalling pathways essential for cellular proliferation, survival and differentiation. Activation of EGFR also initiates events leading to its endocytosis1,2. Receptors, once internalized, are delivered to the endosomal system, from where they are either recycled to the cell surface or sorted to lysosomes for degradation3,4,5. Endocytic trafficking serves as an important determinant of the intensity and duration of EGFR signalling.
Recent studies have shown that the endosomal sorting complexes required for transport, ESCRT-0, -I, -II and -III, are involved in the endosomal sorting of ubiquitinated EGFR to lysosomes through multivesicular bodies (MVBs)6,7,8,9,10. The ESCRT-0 complex, which is composed of hepatocyte growth factor-regulated substrate (Hrs) and signal-transducing adaptor molecule (STAM), is believed to initiate the process by which EGFR is targeted to lysosomes at the early endosome stage. This targeting involves the clustering of ubiquitinated EGFR underneath a clathrin microdomain by recruiting the ESCRT-I complex to the surface of endosomes. Binding of ESCRT-I to the surface of endosomes leads to the sequential recruitment of ESCRT-II and ESCRT-III complexes. These complexes function sequentially in the formation of MVB vesicles and in the sorting of EGFR into the MVB pathway. Thus, the recognition of EGFR by the ESCRT-0 complex is a critical step in the sorting of EGFR to lysosomes.
Human LRRK1 and LRRK2 belong to the ROCO family of proteins and contain a Roc (Ras in complex proteins) domain together with a MAPKKK-like kinase domain and several protein–protein interaction domains. Recently, LRRK2 has been reported to be involved in the pathogenesis of familial Parkinson's disease11,12. However, the functions of LRRK1 and LRRK2 remain unknown.
In this study, we identified Grb2, which is known to be essential for EGFR signalling and endocytosis1,13,14,15,16, as an LRRK1-interacting protein. We demonstrate that LRRK1 participates in the intracellular trafficking of EGFR through an interaction with Grb2. Our findings indicate that LRRK1 regulates transport and sorting of EGFR in a manner dependent on and independent of its kinase activity, respectively.
Results
LRRK1 forms a complex with activated EGFR via Grb2
To investigate the physiological roles of LRRK1, we attempted to identify molecules with which it interacts. We used liquid chromatography-coupled tandem mass spectrometry (LC–MS/MS)17, and identified multiple peptides (Supplementary Table S1). Among the proteins identified, we focused on the Grb2 protein. To confirm the association between LRRK1 and Grb2, COS7 cells were co-transfected with Flag-LRRK1 and HA-Grb2. As seen in Figure 1a, Flag-LRRK1 associated with HA-Grb2. This association was specific for LRRK1, because LRRK2 did not interact with Grb2 (Fig. 1a).
Grb2 contains a single SH2 domain flanked by two SH3 domains14. We examined whether the SH2 or SH3 domain is required for interaction with LRRK1. Mutations in the amino (N)-terminal SH3 (P49L) or SH2 (S90N) domain of Grb2 had no effect on its interaction with LRRK1 (Fig. 1a). In contrast, a mutation in its carboxy (C)-terminal SH3 domain (G203R) resulted in the loss of detectable binding to LRRK1 (Fig. 1a). Thus, interaction of Grb2 with LRRK1 requires the C-terminal SH3 domain of Grb2. We next examined which region of LRRK1 is required for its association with Grb2. We constructed several deletion mutants of LRRK1 (Fig. 1b) and analysed their binding to Grb2. C-terminal-deleted mutants LRRK1(1–1163) and LRRK1(1–595), but not the N-terminal-deleted mutant LRRK1(1164–1989), bound to Grb2 (Supplementary Fig. S1). It is known that the SH3 domain of Grb2 binds to the proline-based motif PXXP14. As the LRRK1(1–595) fragment contains two PXXP motifs, which are located at residues 88–91 and 119–122 (Fig. 1b), we examined whether these sites are responsible for Grb2 association. We found that mutation of the Pro residues in both PXXP motifs to Ala (mutant LRRK1(P88A/P91A/P119A/P122A); LRRK1(4PA)) eliminated binding to Grb2 (Fig. 1c). These results indicate that LRRK1 associates with Grb2 through an interaction between the PXXP motifs of LRRK1 and the C-terminal SH3 domain of Grb2. Using a polyclonal anti-LRRK1 antibody that we generated (Supplementary Fig. S2), we also investigated the interaction of endogenously expressed LRRK1 and Grb2. We found that endogenous LRRK1 was able to associate with endogenous Grb2 in a ligand-independent manner (Fig. 1d).
Because Grb2 functions as an adaptor protein facilitating the association of several factors with activated EGFR14,15, we examined whether LRRK1 forms a complex with EGFR in response to EGF stimulation. COS7 cells were transfected with GFP-LRRK1. We found that GFP-LRRK1 bound to EGFR in a stimulus-dependent manner (Fig. 1e). In contrast, the Grb2-binding-defective mutant GFP-LRRK1(4PA) was unable to associate with EGFR after EGF stimulation (Fig. 1e), suggesting that Grb2 mediates the interaction between LRRK1 and EGFR. We also found that endogenous LRRK1 was able to form a complex with EGFR following EGF stimulation (Fig. 1f). Furthermore, when cells were depleted of Grb2 by transfection with small interfering RNA (siRNA), LRRK1 was unable to interact with EGFR in response to EGF stimulation, regardless of where endogenous or overexpressed LRRK1 was used (Fig. 1f; Supplementary Fig. S3). Taken together, these results demonstrate that LRRK1 forms a complex with EGFR in response to EGF stimulation in a Grb2-dependent manner.
LRRK1 co-localizes with EGF in early endosomes
To investigate the role of LRRK1 in EGFR signalling, we examined the subcellular localization of LRRK1. Because our polyclonal anti-LRRK1 antibody did not provide a sensitive enough detection of the endogenous protein by immunostaining, we used an epitope-tagged LRRK1. We expressed GFP-LRRK1 in HeLa cells and assessed LRRK1 localization by immunofluorescence under basal and EGF-stimulated conditions, together with a fluorescently labelled rhodamine-conjugated EGF (EGF-Rh). LRRK1 was diffusely distributed in cells not treated with EGF-Rh (Fig. 2a). When cells were stimulated with EGF-Rh for 15 min, GFP-LRRK1 became distributed in a fine, punctate pattern that co-localized with EGF-Rh. A large portion of GFP-LRRK1 overlapped with the early endosomal marker autoantigen 1 (EEA1) receptor (Fig. 2b; Supplementary Fig. S4).
We next analysed the ability of Grb2 to affect the intracellular localization of LRRK1 in EGF-stimulated cells. When Grb2 was depleted from HeLa S3 cells using siRNA, EGF-induced localization of LRRK1 in EEA1-positive early endosomes was greatly decreased (Fig. 2c,d; Supplementary Fig. S5a). This suggests that Grb2 is required for the EGF-induced translocation of LRRK1 to early endosomes. Consistent with this, LRRK1(4PA), which is defective for Grb2 binding, failed to localize to early endosomes in response to EGF stimulation (Fig. 2e; Supplementary Fig. S5b). Thus, EGF-induced localization of LRRK1 to early endosomes is dependent on Grb2-mediated complex formation with activated EGFR.
LRRK1 regulates EGFR transport from early to late endosomes
Given the EGF-dependent association of LRRK1 with the early endosome, we reasoned that LRRK1 might function by affecting the endocytic trafficking of EGFR. To test this idea, we monitored the endocytic movement of EGF in cells depleted of LRRK1 by siRNA. HeLa S3 cells incubated with LRRK1 siRNA had a much lower expression of LRRK1 (Supplementary Fig. S6). HeLa S3 cells treated with control or LRRK1 siRNA were stimulated with fluorescent EGF (Alexa 647-EGF) briefly, followed by washing to remove labelled EGF from the medium. Under these conditions, the fluorescence detected in cells was due to endocytosed EGFR bound to labelled growth factor. In LRRK1-depleted cells, the initial localization of EGF to clathrin-coated pits occurred normally, similar to control cells (Supplementary Fig. S7). Thus, depletion of LRRK1 has little obvious effect on the internalization of EGF/EGFR.
Because it is known that Rab5 and Rab7 primarily associate with early and late endosomes, respectively, we coexpressed GFP-Rab5 and DsRed-Rab7 in HeLa S3 cells to visualize early and late endosomes. In this experiment, we used the monomer version of DsRed. Most of the Rab5-positive endosomes were distributed in the cell periphery, whereas Rab7-positive endosomes were more common in the perinuclear region (Fig. 3a–d). In control siRNA-transfected cells, at 10 min after a brief pulse of Alexa 647-EGF stimulation, most of the EGF was found in early endosomes, as evidenced by their co-localization with Rab5 (Fig. 3a,e; Supplementary Fig. S8a). After 15 min, EGF dissociated from the early endosomes, as illustrated by decreased co-localization with Rab5. Remarkably, this decreased co-localization with Rab5 was accompanied by an increase in the co-localization with Rab7 (Fig. 3b,e and f; Supplementary Fig. S8b), suggesting the progression of EGFR to the late-endosomal compartments. In LRRK1-depleted cells, the early endosomal localization of EGF occurred normally, as in control cells (Fig. 3c,e; Supplementary Fig. S8c). However, after 15 min of stimulation, Alexa 647-EGF remained associated with Rab5-positive structures and Rab7 co-localization did not increase (Fig. 3d–f; Supplementary Fig. S8d). This suggests that the transport of EGFR towards late endosomes is inhibited in LRRK1-deficient cells. Thus, LRRK1 is required for the progression of EGFR from early to late endosomes.
LRRK1 regulates the motility of EGF-early endosomes
Because maturation of early to late endosomes is accompanied by the movement of endosomes towards the cell centre18,19,20, we examined the effect of LRRK1 knockdown on the movement of EGF-containing early endosomes. Using time-lapse confocal fluorescence microscopy, movement of EGF-containing early endosomes was followed in cells expressing GFP-Rab5 at 15 min after a brief pulse of Alexa647-EGF. In addition to short-range movement, long-range rapid movement of EGF-positive early endosomes from the periphery to the centre was frequently observed (Fig. 4a,b). When LRRK1 was knocked down by siRNA, long-range rapid movement of EGF-containing early endosomes was remarkably disrupted (Fig. 4c,d). In control cells, 39.7% of GFP-Rab5- and Alexa 647-EGF-double-positive endosomes moved more than 3.0 μm during the imaging time (35 s), but this fraction decreased to only 2.4% in LRRK1-depleted cells (Fig. 4e). We further confirmed this effect of knocking down LRRK1 on the frequency of long-range movement of EGF using a different LRRK1 siRNA in different HeLa cell lines (Supplementary Fig. S9). These observations suggest that LRRK1 is required for the motility of EGF-containing early endosomes.
The role of Roc and kinase domains in EGFR trafficking
Ras proteins switch between an inactive GDP-bound state and an active GTP-bound state and only the latter interacts with its downstream effectors. Among the best characterized downstream effectors of Ras are the MAPKKKs21. Members of the ROCO protein family contain a Ras GTPase-like (Roc) domain and a MAPKKK domain (Fig. 1b). The Roc domain likely serves as a molecular switch, regulating kinase activity by cycling between GDP-bound and GTP-bound states22,23,24. To test whether the Roc domain of LRRK1 also regulates its kinase activity, we generated LRRK1(S625N) (Fig. 1b), in which Ser-625 in the Roc domain of LRRK1 has been mutated to Asn, on the basis of homology to Ras25. We confirmed that the LRRK1(S625N) form lost the ability to bind to GTP sepharose (Supplementary Fig. S10a) and was defective in kinase activity, similar to a kinase-inactive LRRK1(K1243M) (Fig. 1b; Supplementary Fig. S10b). These results are consistent with a model wherein the Roc domain regulates the activity of the kinase domain.
We next examined whether LRRK1(K1243M) or LRRK1(S625N) could rescue the defect in EGFR trafficking caused by LRRK1 knockdown. A large fraction of EGF dissociated from early endosomes 20 min after EGF-Rh stimulation in control siRNA-treated cells (Supplementary Fig. S11a), whereas the EGF remained localized in early endosomes in LRRK1 siRNA-treated cells (Supplementary Fig. S11b), as evidenced by their co-localization with EEA1. Expression of siRNA-resistant wild-type GFP-LRRK1 in LRRK1-depleted cells decreased co-localization of EGF with EEA1 and somewhat enhanced the transport of EGF towards the cell centre at 20 min after EGF-Rh stimulation (Supplementary Fig. S11c), suggesting that EGF was localized in late endosomes. When siRNA-resistant GFP-LRRK1(K1243M) or GFP-LRRK1(S625N) was reintroduced into LRRK1-depleted cells, most of the EGF remained co-localized with EEA1 even after a chase of 20 min (Supplementary Fig. S11d,e). Furthermore, we found that siRNA-resistant wild-type GFP-LRRK1, but not GFP-LRRK1(K1232M), was able to rescue the movement of EGF in LRRK1-depleted cells (Supplementary Fig. S12). These results suggest that the kinase function of LRRK1 is required for the transport of EGF/EGFR from early to late endosomes.
The relationship between LRRK1 and the ESCRT-0 complex
Trafficking of EGF/EGFR in early endosomes is initiated by the interaction of ubiquitinated EGFR with components of the ESCRT-0 complex, STAM and Hrs6,7,8,9,10. To determine whether the effect of LRRK1 on EGFR trafficking involves these endosomal sorting components, we examined the interaction of LRRK1 with STAM and Hrs. COS7 cells were transfected with GFP-LRRK1 and stimulated with EGF. Coimmunoprecipitation experiments revealed that LRRK1 associated with endogenous STAM1 and that this interaction was increased by EGF stimulation (Fig. 5a). Furthermore, we found that endogenous LRRK1 was coimmunoprecipitated with endogenous Hrs in an EGF stimulation-dependent manner (Fig. 5b). These results demonstrate that LRRK1 interacts with the ESCRT-0 complex in response to EGF stimulation.
To determine which regions are responsible for the LRRK1–STAM1 interaction, we constructed several deletion mutants of STAM1 (Fig. 5c). Coimmunoprecipitation assays showed that the coiled-coil domain of STAM1 was important for its interaction with LRRK1 (Fig. 5d). We next tested whether the kinase function of LRRK1 would affect its interaction with STAM1. We found that Flag-STAM1 coimmunoprecipitated with GFP-LRRK1(K1243M) (Fig. 5e), indicating that LRRK1 kinase activity is not required for its association with STAM1. In addition, the Grb2-binding-defective mutant GFP-LRRK1(4PA) was also able to associate with STAM1 (Fig. 5e), suggesting that different regions of LRRK1 interact with Grb2 and STAM1. We next examined whether LRRK1, EGFR and STAM1 exist in the same complex. Flag-STAM1 and Myc-LRRK1 or Myc-LRRK1(K1243M) were coexpressed in COS7 cells and ternary complex formation was investigated via two-step immunoprecipitation. Both Myc-LRRK1 and Myc-LRRK1(K1243M) were able to form a ternary complex with EGFR and STAM1 in response to EGF stimulation (Fig. 5f), indicating that LRRK1 kinase activity is not required for formation of this ternary complex. Given the results showing that LRRK1 interacts with EGFR and the ESCRT-0 complex, we reasoned that loss of LRRK1 should also result in decreased EGFR–ESCRT-0 complex formation. When cells were treated with LRRK1 siRNA, we observed a reduction in the EGF-dependent interaction of activated EGFR with Flag-STAM1 (Fig. 5g). Taken together, these results suggest that LRRK1, by interacting with both Grb2 and the Hrs–STAM1 complex simultaneously, functions as a scaffolding protein linking activated EGFR to the ESCRT-0 complex.
To further evaluate the interaction between LRRK1 and STAM, we examined the potential co-localization of LRRK1 and STAM1 in early endosomes. Previous studies have revealed that Hrs accumulates in restricted microdomains on the endosome membrane, strongly co-localizing with clathrin26,27,28,29. By contrast, EEA1-containing regions of the endosome membrane are largely devoid of Hrs and clathrin. To study these endosomal microdomains, HeLa S3 cells were transfected with a constitutively active form of Rab5(Q79L), to increase the fusion rate of endosomes30. High Rab5 activity results in enlarged early endosomes on which microdomains can be easily distinguished by confocal immunofluorescence microscopy26,27,29,31. STAM1 co-localized strongly with clathrin on the enlarged endosomes (Supplementary Fig. S13a), whereas there was little co-localization of STAM1 and EEA1 (Supplementary Fig. S13b). These results suggest that STAM1 participates together with Hrs in the sorting of ubiquitinated cargo in clathrin-coated microdomains of early endosomes. GFP-LRRK1 was mainly distributed to the cytosol in the absence of EGF stimulation (Fig. 6a). However, LRRK1 localization was restricted to the enlarged endosomes of EGF-treated cells, and we could detect a certain degree of localization of GFP-LRRK1 to STAM1-positive microdomains (Fig. 6b). We also found that EGFR co-localized with STAM1 on Rab5(Q79L)-induced enlarged endosomes after EGF stimulation (Fig. 6c). To investigate whether LRRK1 is important for the recruitment of EGFR into STAM1-positive microdomains, we set out to study the relative localizations of EGFR and STAM1 in LRRK1-depleted cells. In such LRRK1-depleted cells, both EGFR and STAM1 could still be detected on endosomes. Interestingly, however, LRRK1-depleted endosomes appeared to show decreased co-localization of EGFR and STAM1 (Fig. 6d). Furthermore, this co-localization gradually increased at the later phase of EGF stimulation (Fig. 6e), indicating that LRRK1 depletion delays EGFR-STAM1 co-localization. We confirmed the effect of LRRK1 depletion on the co-localization of Alexa 647-EGF and STAM1 by three-dimensional reconstruction of confocal Z-stack images (Supplementary Fig. S14). These results suggest that LRRK1 determines the efficiency of recruitment by serving as a scaffolding function on the endosomal membrane to restrict EGFR localization to STAM-positive microdomains.
LRRK1 modulates the ubiquitination status of STAM1
The sorting of ubiquitinated EGFR is initiated by the recognition of EGFR ubiquitin (Ub) moieties by the Ub-interacting motifs (UIMs) within Hrs and STAM10,32. Hrs and STAM themselves are also ubiquitinated32,33, and a recent study has suggested that intramolecular binding between UIMs and Ub prevents Hrs from binding in trans to ubiquitinated EGFR32. We therefore examined the effect of LRRK1 knockdown on the ubiquitination status of STAM1. We co-transfected HeLa S3 cells with Flag-STAM1 and HA-Ub. In control siRNA cells, we could detect weak ubiquitination of STAM1 and this ubiquitination was enhanced by EGF stimulation (Fig. 7a). Depletion of LRRK1 resulted in hyper-ubiquitination of STAM1 (Fig. 7a). Thus, depletion of LRRK1 results in the enhancement of Ub modification in STAM1. We then examined the effect of LRRK1 overexpression on the ubiquitination status of STAM1. We found that overexpression of LRRK1 inhibited ubiquitination of STAM1 (Fig. 7b). In addition, overexpression of kinase-negative LRRK1(K1243M) was able to inhibit STAM1 ubiquitination (Fig. 7b), suggesting that LRRK1 kinase activity is not necessary for this reaction.
We next attempted to narrow down the region(s) where STAM1 is ubiquitinated, using various deletion mutants of STAM1 (Fig. 5c). Ubiquitination assays revealed that the N-terminal Ub-binding domains (VHS and UIM) and the SH3 domain of STAM1 are important for monoubiquitination, and that the coiled-coil domain contains the majority of polyubiquitination sites in STAM1 (Fig. 7c). Thus, the coiled-coil domain of STAM1 is involved in both its interaction with LRRK1 and its ubiquitination, raising the possibility that LRRK1 inhibits STAM1 ubiquitination by associating with its coiled-coil domain.
The coiled-coil domain in STAM1 has five lysine residues (Fig. 7d). To confirm the importance of the coiled-coil domain for STAM1 ubiquitination, we generated STAM1(5KR), in which all these five lysines have been mutated to arginines. STAM1(5KR) was impaired in polyubiquitination but not in monoubiquitination (Fig. 7d). These results suggest that the lysine residues in the coiled-coil domain of STAM1 are polyubiquitinated. The above results suggested that LRRK1 affects the interaction between EGFR and STAM1 by modulating the ubiquitination status of STAM1. Consistent with this, STAM1(5KR) showed an increase in its interaction with activated EGFR compared with wild-type STAM1 (Fig. 7e). Taken together, these results suggest that LRRK1 functions as a scaffolding protein linking activated EGFR to the ESCRT-0 complex by suppressing the polyubiquitination of STAM1.
LRRK1 regulates sorting of EGF/EGFR into intraluminal vesicles of MVBs
EGFR localized in clathrin-coated microdomains on endosomes is sorted into intraluminal vesicles (ILVs) within MVBs and delivered to lysosomes for degradation. We therefore examined whether LRRK1 knockdown affects the sorting of EGFR into ILVs of enlarged endosomes using three-dimensional reconstructions. In control siRNA-transfected cells, Alexa 647-EGF was translocated from the limiting membrane to ILVs of Rab5(Q79L)-induced enlarged endosomes at 30 min after EGF stimulation (Fig. 8a). In contrast, depletion of LRRK1 reduced the intraluminal transport of Alexa 647-EGF into enlarged endosomes (Fig. 8b). Line intensity profiles of individual endosomes clearly showed that most of the EGF was localized within the inner membranes in control cells (Fig. 8c), but were retained in the limiting membrane in LRRK1-depleted cells (Fig. 8d). Quantification of EGF labelling showed that about 66.2% of the labelling was localized to the inner membranes in cells treated with control siRNA, whereas only 16.7% showed this localization in cells treated with LRRK1 siRNA (Fig. 8e). These results demonstrate that LRRK1 is needed for sorting of EGF/EGFR into ILVs of MVBs. When siRNA-resistant, wild-type GFP-LRRK1 was expressed in LRRK1-depleted cells, the defect in the intraluminal transport of Alexa 647-EGF was partially rescued (Fig. 8e). However, expression of the siRNA-resistant, kinase-negative GFP-LRRK1(K1243M) was able to rescue the defect in EGF sorting in LRRK1-depleted cells (Fig. 8e), suggesting that LRRK1 kinase activity is not essential for this step. Thus, LRRK1 functions as a scaffold in this process, independent of its kinase activity.
We confirmed the above immunofluorescence data by electron microscopy. Silver-enhanced gold particles revealed the presence of endogenous EGFR associated with both the limiting membrane and ILVs of MVBs in control cells, whereas most of the EGFR was still located on the limiting membrane of MVBs in LRRK1-depleted cells (Fig. 8f). We next asked whether LRRK1 could also affect EGFR degradation. Although EGF stimulation normally causes the degradation of EGFR, we observed stabilization of activated EGFR in cells treated with LRRK1 siRNA (Fig. 8g). These results suggest that LRRK1 is required for EGFR sorting into the degradative pathway.
Discussion
EGFR targeted for lysosomal degradation is delivered to MVBs by a highly specialized process that begins with receptor ubiquitination and sequestration by elements of the ESCRT complex on the surface of early endosomes6,7,8,9,10. Endosomal sorting of ubiquitinated EGFR is initiated by ESCRT-0, which is composed of Hrs and STAM6,7,8,9,10. It has been proposed that Hrs and STAM can concentrate ubiquitinated cargo on clathrin-coated microdomains of early endosomes and link the cargo with the subsequent ESCRT machinery that is required for proper sorting27,29,31. In this study, we show that LRRK1 is required for EGFR transport from early to late endosomes. Our results demonstrate that LRRK1 forms a complex with EGFR via Grb2 and associates with STAM and Hrs in response to ligand stimulation. Furthermore, we find that knockdown of LRRK1 disrupts the recruitment of EGFR to STAM1-positive microdomains of early endosomes, leading to the inhibition of EGFR sorting to the inner vesicles of MVBs. LRRK1 may function as a scaffolding protein between ubiquitinated EGFR and the Hrs–STAM1 complex. Consistent with this possibility, EGFR, LRRK1 and STAM1 can form a ternary complex in response to EGF stimulation, and knockdown of LRRK1 disrupts the interaction of EGFR with STAM1. In addition, our data suggest a mechanism whereby LRRK1 modulates the ubiquitination status of STAM1 by direct interaction. It is likely that ubiquitination of STAM1, which leads to intramolecular binding within STAM1, inhibits its ability to interact with ubiquitinated EGFR. Therefore, LRRK1 promotes complex formation between activated EGFR and STAM1 by decreasing the ubiquitination of STAM1. Our findings suggest that LRRK1 might function as a cargo-specific factor that efficiently links the activated EGFR to the ESCRT machinery.
Remarkably, we find that the motility of EGF-containing early endosomes is diminished dramatically by LRRK1 knockdown. We demonstrate that LRRK1 kinase activity is required for the transport of EGFR-containing early endosomes from the periphery to the centre. Recent studies have shown that early endosomes move towards the cell centre as they mature18,20. The movement of early endosomes is mediated by cytoplasmic dynein, a minus end-directed microtubule motor19,34. LRRK1 might thus be involved in the regulation of dynein-dependent transport of EGF-containing early endosomes. Interestingly, in a screen for LRRK1-binding proteins, we have identified NudC and CLIP-170, which are involved in dynein-mediated processes35,36. Thus, LRRK1 might regulate the motility of EGF-containing early endosomes by phosphorylating these candidates.
Because excessive or inappropriate signalling by activated EGFR is associated with the development of a broad range of human cancers, the spatiotemporal regulation of EGFR trafficking by LRRK1 is likely to be important for the maintenance of cellular homoeostasis. Identification of specific LRRK1 targets involved in the regulation of EGFR trafficking in early endosomes will be necessary. Further analysis of LRRK1 function may shed new light on the molecular mechanisms regulating the intracellular trafficking of EGFR, and thus the spatiotemporal control of EGFR signalling.
Methods
Plasmids and mutations
Human LRRK1 cDNA was subcloned into vector pGFP-C1 (Clontech), pCMV or pCS2. LRRK1(4PA), LRRK1(K1243M) and LRRK1(S625N) were generated using the QuickChange Site-Directed Mutagenesis Kit according to the manufacturer's protocol (Stratagene). siRNA-resistant LRRK1 was generated by mutating the target sequence of the LRRK1 siRNA (5′-GCAGGAACAGGAAAGTCACCATTTA-3′) into 5′-GTCGAAATCGAAAAGTCACCATTTA-3′. Human LRRK2 (Park8) cDNA was subcloned into vector pCMV. HA-Grb2(P49L), HA-Grb2(S90N), HA-Grb2(G203R) and HA-Grb2(P49L/G203R) were generated using the mutagenesis kit described above and subcloned into vector pSRα37. Human Rab5 and Rab7 were subcloned into vector pGFP-C1 or pDsRed-C1 (Clontech; catalogue number 632466), and Rab5(Q79L) was generated using the mutagenesis kit described above. pDsRed-C1 produces the monomer form of DsRed. Deletion constructs of STAM1 were generated by PCR-based mutagenesis and subcloned into pCMV-Flag.
Antibodies and reagents
Rabbit antibodies against LRRK1 were produced by MBL (Medical and Biological Laboratories) by injecting rabbits with synthetic peptides corresponding to residues 1767–1783 and 1848–1865 of LRRK1 coupled to keyhole limpet haemocyanin. Antibodies and their suppliers were as follows: anti-HA (16B12, Babco); anti-Flag (M2, Sigma); anti-Myc (9E10, Santa Cruz Biotechnology); anti-GFP (JL-8 or Full-length polyclonal antibody, Clontech); anti-phospho-Tyr (4G10, Upstate Biotechnology); anti-EGFR (SC-03, Santa Cruz Biotechnology, LA22, Upstate Biotechnology or 6F1, MBL); anti-Grb2 (SC-23, Santa Cruz Biotechnology); anti-EEA1 (Clone 14, BD Transduction Laboratories); anti-STAM1 (H-175, Santa Cruz Biotechnology); anti-Hrs (A-5, Alexis Biochemicals); anti-clathrin (clone 23, BD Transduction Laboratories); anti-Tubulin (B-5-1-2, Sigma); Goat anti-mouse IgM conjugated to 10 nm gold (BBinternational). EGF-Rh and Alexa647-EGF were purchased from Molecular Probes and human recombinant EGF from TOYOBO.
Cell cultures and transfections
HeLa, HeLa S3, HEK293 and COS7 cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. These cells were split on 35-mm, 60-mm or 100-mm dishes at 2×105, 5×105 or 2×106 cells per dish, respectively. After 19 h, cells were transfected using RNAi MAX (Invitrogen) or FuGENE 6 reagent (Roche Applied Science) according to the manufacturer's protocol.
Immunoprecipitation
For immunoprecipitation, cells were lysed in RIPA buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA, 2 mM dithiothreitol, 1 mM phenylmethylsulphonyl fluoride, phosphatase inhibitor cocktail 2 (Sigma) and protease inhibitor cocktail (Sigma), followed by centrifugation at 15,000 g for 15 min. The supernatant was added to 10 μl (bed volume) of protein G sepharose beads (GE Healthcare) or Dynabeads protein G (Invitrogen) with the indicated antibodies and rotated for 2 h at 4°C or for 10 min at room temperature. The beads were washed three times with ice-cold phosphate-buffered saline and subjected to immunoblotting or kinase assays.
Immunoblotting
After the extracts were subjected to SDS–polyacrylamide gel electrophoresis (SDS–PAGE), proteins were transferred to polyvinylidene difluoride membrane (Hybond-P, GE Healthcare). Membranes were incubated with indicated antibodies using the SNAP i.d. system (Millipore). Immunoreactive bands were detected by an HRP chemiluminescent substrate reagent kit (Novex ECL, Invitrogen).
In vitro autophosphorylation assay
Immunocomplex kinase reactions of GFP-LRRK1, GFP-LRRK1(K1243M) or GFP-LRRK1(S625N) were performed in a final volume of 20 μl containing 20 mM Tris-HCl (pH7.4), 5 mM EGTA, 15 mM MgCl2, 5 μCi of [γ-32P]ATP. Samples were incubated for 20 min at 30°C. Reactions were terminated by the addition of Laemmli sample buffer and boiling. GFP-LRRK1, GFP-LRRK1(K1243M) or GFP-LRRK1(S625N) was resolved by SDS–PAGE. Autophosphorylation of LRRK1 was detected by autoradiography.
RNA interference
siRNA targeted against human LRRK1, human Grb2 and negative control siRNAs were purchased from Invitrogen and Ambion. Stealth siRNA (Stealth#1) for human LRRK1 (target sequence: 3165gcaggaacaggaaagtcaccattta TT), Silencer Validated siRNA (Ambion#1) for human LRRK1 (target sequence: 5493ggaatcactcactgactac TT) and Custom siRNA for human Grb2 (target sequence: 607catgtttccccgcaattat TT)15 were used. Annealed siRNAs were transfected using RNAiMAX (Invitrogen). The transfected cells were analysed 72 h after transfection. For immunofluorescence experiments, cells were transfected with control siRNA, Grb2 siRNA or LRRK1 siRNA using RNAiMAX, incubated overnight and then transfected with GFP-LRRK1, GFP-Rab5, DsRed-Rab7, GFP-Rab5(Q79L) or DsRed-Rab5(Q79L) in the indicated combinations, using FuGENE 6 reagent (Roche Applied Science).
GTP-binding studies
Cells were lysed at 48 h post transfection in lysis buffer G (100 mM Tris-HCl pH 7.5, 50 mM KCl, 1 mM EDTA, 0.1 mM dithiothreitol, 5 mM MgCl2, 1% Triton X-100) containing phosphatase inhibitor cocktail and protease inhibitor cocktail (Sigma) for 10 min on ice, and lysates were clarified by centrifugation at 15,000 g for 10 min at 4°C. Supernatants were incubated with 20 μl of GTP-sepharose bead suspension (Sigma) by rotating at 4°C for 2 h and then sequentially pelleted and washed three times with 1 ml PBS. For guanine nucleotide competition experiments, GTP (Sigma) was added to a final concentration of 2 mM, and incubation was continued for a further 60 min at 4°C followed by washing. Precipitated proteins were resolved by SDS–PAGE and immunoblotted with anti-GFP antibodies.
Fluorescence microscopy
For immunofluorescence microscopy, cells grown on coverslips were treated, as indicated, and then fixed in 4% paraformaldehyde, permeabilized in 0.5% Triton X-100 and incubated with primary and secondary antibodies. Primary antibodies were anti-EEA1 at 1:100, anti-EGFR at 1:100, anti-STAM1 at 1:250 and anti-clathrin at 1:100. Secondary antibodies were Alexa-Fluor 647 goat anti-mouse IgG, Alexa-Fluor 555 goat anti-mouse IgG and Alexa-Fluor 488 goat anti-mouse IgG (Molecular Probes). Confocal microscopy was performed using an Olympus FV1000 microscope. For live-cell fluorescence microscopy, cells were grown in 35-mm plastic-bottomed dishes. Time-lapse images were obtained with a laser scanning confocal microscope (FV1000; Olympus). Tracking of GFP-Rab5- and A647-EGF-positive endosomes was conducted using the 'Manual Tracking' Image J plug-in (National Institutes of Health).
Conventional electron microscopy
Conventional electron microscopy was performed as described previously38. In brief, cells were fixed in 2.5% glutaraldehyde in 0.1 M sodium phosphate buffer at pH 7.4 for 20 min. The specimens were postfixed in buffer containing 1% OsO4, dehydrated in a series of graded ethanol solutions and embedded in epoxy resin. Ultrathin sections were collected and stained with uranylacetate and lead citrate and observed under an H7600 transmission electron microscope (Hitachi).
Additional information
How to cite this article: Hanafusa, H. et al. Leucine-rich repeat kinase LRRK1 regulates endosomal trafficking of the EGF receptor. Nat. Commun. 2:158 doi: 10.1038/ncomms1161 (2011).
References
Wang, Z. & Moran, M. F. Requirement for the adaptor protein GRB2 in EGF receptor endocytosis. Science 272, 1935–1939 (1996).
Vieira, A. V., Lamaze, C. & Schmid, S. L. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 274, 2086–2089 (1996).
Maxfield, F. R. & McGraw, T. E. Endocytic recycling. Nat. Rev. Mol. Cell Biol. 5, 121–132 (2004).
Soldati, T. & Schliwa, M. Powering membrane traffic in endocytosis and recycling. Nat. Rev. Mol. Cell Biol. 7, 897–908 (2006).
Mukhopadhyay, D. & Riezman, H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 315, 201–205 (2007).
Katzmann, D. J., Odorizzi, G. & Emr, S. D. Receptor downregulation and multivesicular-body sorting. Nat. Rev. Mol. Cell Biol. 3, 893–905 (2002).
Nickerson, D. P., Russell, M. R. & Odorizzi, G. A concentric circle model of multivesicular body cargo sorting. EMBO Rep. 8, 644–650 (2007).
Williams, R. L. & Urbe, S. The emerging shape of the ESCRT machinery. Nat. Rev. Mol. Cell Biol. 8, 355–368 (2007).
Hurley, J. H. ESCRT complexes and the biogenesis of multivesicular bodies. Curr. Opin. Cell Biol. 20, 4–11 (2008).
Raiborg, C. & Stenmark, H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 458, 445–452 (2009).
Paisan-Ruiz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595–600 (2004).
Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601–607 (2004).
Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211–225 (2000).
Pawson, T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116, 191–203 (2004).
Jiang, X., Huang, F., Marusyk, A. & Sorkin, A. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol. Biol. Cell 14, 858–870 (2003).
Waterman, H. et al. A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J. 21, 303–313 (2002).
Natsume, T. et al. A direct nanoflow liquid chromatography-tandem mass spectrometry system for interaction proteomics. Anal. Chem. 74, 4725–4733 (2002).
Rink, J., Ghigo, E., Kalaidzidis, Y. & Zerial, M. Rab conversion as a mechanism of progression from early to late endosomes. Cell 122, 735–749 (2005).
Driskell, O. J., Mironov, A., Allan, V. J. & Woodman, P. G. Dynein is required for receptor sorting and the morphogenesis of early endosomes. Nat. Cell Biol. 9, 113–120 (2007).
Woodman, P. G. & Futter, C. E. Multivesicular bodies: co-ordinated progression to maturity. Curr. Opin. Cell Biol. 20, 408–414 (2008).
Chang, L. & Karin, M. Mammalian MAP kinase signalling cascades. Nature 410, 37–40 (2001).
Smith, W. W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T. M. & Ross, C. A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9, 1231–1233 (2006).
Ito, G. et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochem. 46, 1380–1388 (2007).
Weiss, B. ROCO kinase activity is controlled by internal GTPase function. Sci. Signal. 1, pe27 (2008).
Bourne, H. R., Sanders, D. A. & McCormick, F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 349, 117–127 (1991).
Raiborg, C., Bache, K. G., Mehlum, A., Stang, E. & Stenmark, H. Hrs recruits clathrin to early endosomes. EMBO J. 20, 5008–5021 (2001).
Raiborg, C., Bache, K. G., Gillooly, D. J., Madshus, I. H., Stang, E. & Stenmark, H. Hrs sorts ubiquitinated proteins into clathrin-coated microdomains of early endosomes. Nat. Cell Biol. 4, 394–398 (2002).
Urbe, S. et al. The UIM domain of Hrs couples receptor sorting to vesicle formation. J. Cell Sci. 116, 4169–4179 (2003).
Raiborg, C., Wesche, J., Malerod, L. & Stenmark, H. Flat clathrin coats on endosomes mediate degradative protein sorting by scaffolding Hrs in dynamic microdomains. J. Cell Sci. 119, 2414–2424 (2006).
Stenmark, H., Parton, R. G., Steele-Mortimer, O., Lutcke, A., Gruenberg, J. & Zerial, M. Inhibition of rab5 GTPase activity stimulates membrane fusion in endocytosis. EMBO J. 13, 1287–1296 (1994).
Bache, K. G., Raiborg, C., Mehlum, A. & Stenmark, H. STAM and Hrs are subunits of a multivalent ubiquitin-binding complex on early endosomes. J. Biol. Chem. 278, 12513–12521 (2003).
Hoeller, D. et al. Regulation of ubiquitin-binding proteins by monoubiquitination. Nat. Cell Biol. 8, 163–169 (2006).
Polo, S. et al. A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins. Nature 416, 451–455 (2002).
Aniento, F., Emans, N., Griffths, G. & Gruenberg, J. Cytoplasmic dynein-dependent vesicular transport from early to late endosomes. J. Cell Biol. 123, 1373–1387 (1993).
Yamada, M. et al. mNUDC is required for plus-end-directed transport of cytoplasmic dynein and dynactins by kinesin-1. EMBO J. 29, 517–531 (2010).
Lomakin, A. J. et al. CLIP-170-dependent capture of membrane organelles by microtubules initiates minus-end directed transport. Dev. Cell 17, 323–333 (2009).
Hanafusa, H., Torii, S., Yasunaga, T. & Nishida, E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat. Cell Biol. 4, 850–858 (2002).
Hayashi-Nishino, M., Fujita, N., Noda, T., Yamaguchi, A., Yoshimori, T. & Yamamoto, A. A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation. Nat. Cell Biol. 11, 1433–1437 (2009).
Acknowledgements
We thank A. Yamamoto and N. Hisamoto for helpful discussion and K. Tanaka and T. Yamamoto for providing materials. This research was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to K.M. and H.H.), as well as from the Nakajima Foundation, the Uehara Memorial Foundation and the Kato Memorial Bioscience Foundation (to H.H.).
Author information
Authors and Affiliations
Contributions
H.H., K.I., S.K., T.S. and M.K. conducted the experiments. S.-I.L. and T.N. performed the LC–MS/MS. H.S. isolated and mutated the LRRK1 cDNA. A.N. performed the electron microscopy analysis. H.H. and K.M. designed the experiments and wrote the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Information
Supplementary Figures S1-S14 and Supplementary Table S1 (PDF 7803 kb)
Rights and permissions
This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Hanafusa, H., Ishikawa, K., Kedashiro, S. et al. Leucine-rich repeat kinase LRRK1 regulates endosomal trafficking of the EGF receptor. Nat Commun 2, 158 (2011). https://doi.org/10.1038/ncomms1161
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/ncomms1161
This article is cited by
-
Whole exome sequencing in ADHD trios from single and multi-incident families implicates new candidate genes and highlights polygenic transmission
European Journal of Human Genetics (2020)
-
LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson’s disease: a review
Journal of Biomedical Science (2018)
-
iTRAQ analysis of protein profile during the secondary stage of infection of Plasmodiophora brassicae in Chinese cabbage (Brassica rapa subsp. pekinensis)
Journal of Plant Pathology (2018)
-
Role and mechanism of action of leucine-rich repeat kinase 1 in bone
Bone Research (2017)
-
LRRK1 is critical in the regulation of B-cell responses and CARMA1-dependent NF-κB activation
Scientific Reports (2016)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.